Immune checkpoint inhibitor-associated gastritis: Patterns and management

Abstract

Immune checkpoint inhibitors (ICIs) are widely used due to their effectiveness in treating various tumors. Immune-related adverse events (irAEs) are defined as adverse effects resulting from ICI treatment. Gastrointestinal irAEs are a common type of irAEs characterized by intestinal side effects, such as diarrhea and colitis, which may lead to the cessation of ICIs. Although irAE gastritis is rarely reported, it may lead to serious complications such as gastrorrhagia. Furthermore, irAE gastritis is often difficult to identify early due to its diverse symptoms. Although steroid hormones and immunosuppressants are commonly used to reverse irAEs, the best regimen and dosage for irAE gastritis remains uncertain. In addition, the risk of recurrence of irAE gastritis after the reuse of ICIs should be considered. In this editorial, strategies such as early identification, pathological diagnosis, management interventions, and immunotherapy rechallenge are discussed to enable clinicians to better manage irAE gastritis and improve the prognosis of these patients.

Managing immune checkpoint inhibitor-associated gastritis: Insights and strategies

“…I am writing to express my concern regarding the paper titled “Immune checkpoint inhibitor-associated gastritis: Patterns and management” by Lin et al [ 1 ], recently published in the World Journal of Gastroenterology . The authors systematically summarize the occurrence patterns and management strategies of immune checkpoint inhibitor (ICI)-associated gastritis, providing important evidence for research and practice in this field.…”

Gastric microbiota transplantation as a potential treatment for immune checkpoint inhibitor-associated gastritis

“…We read with interest this editorial by Lin et al [ 1 ], who comprehensively introduced therapeutic strategies for immune checkpoint inhibitor (ICI)-associated gastritis. ICI-associated gastroenteritis is often reported among immune-related adverse events (irAEs).…”